ARQL ArQule Inc.

7.89
-0.07  -1%
Previous Close 7.96
Open 7.93
Price To Book 5.89
Market Cap 948,854,438
Shares 120,260,385
Volume 167,566
Short Ratio
Av. Daily Volume 1,681,186

NewsSee all news

  1. ArQule to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on September 24, 2019

    ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will participate in the Oppenheimer Fall Summit

  2. ArQule to Participate in Citi's 14th Annual Biotech Conference on September 4, 2019

    ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Marc Schegerin, Chief Financial Officer, will attend Citi's investor conference on Wednesday, September 4, 2019 at the Four

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 registrational MOSAIC trial to be initiated 3Q 2019.
ARQ 092
Overgrowth Diseases
Phase 1/2 trial ongoing.
Derazantinib (ARQ 087)
intrahepatic cholangiocarcinoma (iCCA)
Phase 3 top-line data released February 17, 2017 - primary endpoint not met.
Tivantinib (ARQ 197) METIV-HCC trial
Previously treated Inoperable Hepatocellular Carcinoma cancer
Phase 1b data due 2H 2019.
Miransertib - ARQ 092
Solid tumors
Phase 1 data at EHA June 14, 2019 noted 66% (4/6) ORR in CLL patients.
ARQ 531
B-cell malignancies
Phase 1b data to be presented 4Q 2019.
ARQ 751
Solid tumors
Phase 1/2 trial to be initiated mid-2019.
Derazantinib (BAL087) and Atezolizumab (Tecentriq)
Urothelial cancer

Latest News

  1. ArQule to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on September 24, 2019

    ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, Chief Medical Officer and Head of Research and Development, will participate in the Oppenheimer Fall Summit

  2. ArQule to Participate in Citi's 14th Annual Biotech Conference on September 4, 2019

    ArQule, Inc. (NASDAQ:ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Marc Schegerin, Chief Financial Officer, will attend Citi's investor conference on Wednesday, September 4, 2019 at the Four